Infection and Impact of Prophylaxis in Sickle Cell Children: A Cross-Sectional Study of 327 Sickle Cell Children Admitted in Emergency Department of Albert Royer Children Hospital in Dakar, Senegal
Background: Pneumococcus has been identified in several studies as the infectious agent most frequently found in children with sickle cell disease. However, some studies note an emergence of other infectious agents, especially in sub-Saharan Africa. Prophylactic measures, mainly targeting pneumococcus, our study aimed to describe the epidemiological, clinical and biological aspects of infections in children with sickle cell disease and to measure the impact of prophylactic anti-infectious measures. Methods: We conducted a cross-sectional study over a 5-month period from January 2022 to May 2022 in children and adolescents with sickle cell disease admitted to the emergency department of Albert Royer Children’s Hospital. Epidemiological, clinical, biological and therapeutic data were collected by Excel and used by SPSS 28.0 software. Results: of the 327 patients seen in the emergency room, 107 (32.7%) were admitted for infection. Pulmonary infection was the most common, with 46 patients (42%), followed by bone infections. Of the 46 blood cultures performed during this period, only one came back positive for pneumococcus. All patients initially received probabilistic antibiotic therapy. Vaccination coverage against pneumococcus was 19.26% in these patients. 60% of children under 5 were on antibiotic prophylaxis. There was a statistically significant association between the absence of vaccination coverage and the occurrence of infection. Conclusion: Infections account for around a third of emergency room admissions for children with sickle cell disease, and are dominated by respiratory and osteoarticular infections. Despite this, coverage of prophylactic measures such as vaccination and antibiotic prophylaxis remains low, due to their cost.
References
[1]
Williams, T.N. and Thein, S.L. (2018) Sickle Cell Anemia and Its Phenotypes. AnnualReviewofGenomicsandHumanGenetics, 19, 113-147. https://doi.org/10.1146/annurev-genom-083117-021320
[2]
Egesa, W.I., Nakalema, G., Waibi, W.M., Turyasiima, M., Amuje, E., Kiconco, G., etal. (2022) Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and beyond. InternationalJournalofPediatrics, 2022, Article ID: 3885979. https://doi.org/10.1155/2022/3885979
[3]
Délicat-Loembet, L.M., Baraïka, M.A., Bougoudogo, F. and Diallo, D.A. (2023) Bacterial Infection in the Sickle Cell Population: Development and Enabling Factors. Microorganisms, 11, Article 859. https://doi.org/10.3390/microorganisms11040859
[4]
Gaston, M.H., Verter, J.I., Woods, G., Pegelow, C., Kelleher, J., Presbury, G., et al. (1986) Prophylaxis with Oral Penicillin in Children with Sickle Cell Anemia. New England Journal of Medicine, 314, 1593-1599. https://doi.org/10.1056/nejm198606193142501
[5]
Faye, F.M. (2021) Couverture sanitaire universelle au Sénégal: Évaluation d’impact et analyse des politiques de financement de la santé. Master’s Thesis, Université Clermont Auvergne.
[6]
Cannas, G. (2019) Sickle Cell Disease and Infections in High-and Low-Income Countries. MediterraneanJournalofHematologyandInfectiousDiseases, 11, Article ID: 02019042. https://doi.org/10.4084/mjhid.2019.042
[7]
Boiro, D., Gueye, M., Thiongane, A., Ndongo, A.A., Houngbadji, M., Keïta, Y., Dieng, Y.J., Seck, N., Basse, I., Benjoloune, A. and Ndiaye, O. (2016) Drépanocytose chez l’enfant. Profils clinique et évolutif à propos de 138 cas suivis au Service de Pédiatrie de l’Hôpital Abass Ndao de Dakar. Médecine d’Afrique Noire, 63, 326-332.
[8]
Dèmely, I., Ba, I.D., Thiongane, A., Tall, G., etal. (2017) Profil épidémiologique et clinique des enfants et adolescents atteints de syndromes drépanocytaires majeurs admis en situation d’urgence en consultation drépanocytose à Dakar. Journal Africain de Pédiatrie et de Génétique Médicale, 3, 44-49.
[9]
Yusuf, I. (2018) Characterization and Antimicrobial Susceptibility Profile of Septicaemia-Causing Pathogens Isolated from Febrile Children with Sickle Cell Disease in Kano, Nigeria. MediterraneanJournalofHematologyandInfectiousDiseases, 10, e2018016. https://doi.org/10.4084/mjhid.2018.016
[10]
Brown, B.J., Dada-Adegbola, H.O., Trippe, C. and Olopade, O. (2017) Prevalence and Aetiology of Bacteremia in Febrile Children with Sickle Cell Disease at a Nigerian Tertiary Hospital. MediterraneanJournalofHematologyandInfectiousDiseases, 9, e2017039. https://doi.org/10.4084/mjhid.2017.039
[11]
Musa, A., Ogunrinde, O.G., Mamman, A.I., Saad, Y.M., Ibrahim, A. and Yakubu, A.M. (2018) Prevalence and Pattern of Bacterial Isolate in Febrile Children with Sickle Cell Anemia in a Tertiary Hospital in Northern Nigeria. Sub-Saharan African Journal of Medicine, 5, 80-85.
[12]
Coria, A.L., Taylor, C.M. and Tubman, V.N. (2020) Fever Management in Sickle Cell Disease in Low-and Middle-Income Countries: A Survey of SCD Management Programs. TheAmericanJournalofTropicalMedicineandHygiene, 102, 902-904. https://doi.org/10.4269/ajtmh.19-0541
[13]
(2018) Medical Experts (Burkina Faso, Mali, Madagascar, Mauritania, Niger, Senegal) with Support from the Principality of Monaco. Guide de prise en charge: la drépanocytose en afrique. https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url= http://ceasamef.sn/wp-content/uploads/2019/09/Guide-La-Drepanocytose-en-Afrique-senegal-.pdf&ved=2ahUKEwjRx-WXxe2LAxWIX_EDHe4aLwgQFnoECBUQAQ&usg=AOvVaw1NvOPDHJCdTnTUDoqtCuZT
[14]
Piel, F.B., Patil, A.P., Howes, R.E., Nyangiri, O.A., Gething, P.W., Dewi, M., etal. (2013) Global Epidemiology of Sickle Haemoglobin in Neonates: A Contemporary Geostatistical Model-Based Map and Population Estimates. TheLancet, 381, 142-151. https://doi.org/10.1016/s0140-6736(12)61229-x
[15]
Yawn, B.P., Buchanan, G.R., Afenyi-Annan, A.N., Ballas, S.K., Hassell, K.L., James, A.H., etal. (2014) Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members. JAMA, 312, 1033-1048. https://doi.org/10.1001/jama.2014.10517
[16]
Thiam, L., Boiro, D., Ndongo, A.A., Niang, B., Seck, N., Demely, I., Ba, A., Basse, I., Diouf, F.N., Drame, A., Coly, I.Z., Houngbadji, M., Diatta, A., Diouf, S., Sylla, A., Diagne, I. and Ndiaye, O. (2018) Complications aiguës des syndromes drépanocytaires majeurs à l’Hôpital de la Paix de Ziguinchor (HPZ), Sénégal. Mt Pédiatrie, 21, 233-237.
[17]
Yee, M.E., Lai, K.W., Bakshi, N., Grossman, J.K., Jaggi, P., Mallis, A., etal. (2021) Bloodstream Infections in Children with Sickle Cell Disease: 2010-2019. Pediatrics, 149, e2021051892. https://doi.org/10.1542/peds.2021-051892
[18]
Ochocinski, D., Dalal, M., Black, L.V., Carr, S., Lew, J., Sullivan, K., etal. (2020) Life-threatening Infectious Complications in Sickle Cell Disease: A Concise Narrative Review. FrontiersinPediatrics, 8, Article 38. https://doi.org/10.3389/fped.2020.00038
[19]
Norris, C.F., Smith-Whitley, K. and McGowan, K.L. (2003) Positive Blood Cultures in Sickle Cell Disease: Time to Positivity and Clinical Outcome. JournalofPediatricHematology/Oncology, 25, 390-395. https://doi.org/10.1097/00043426-200305000-00008
[20]
Shihabuddin, B.S. and Scarfi, C.A. (2014) Fever in Children with Sickle Cell Disease: Are All Fevers Equal? TheJournalofEmergencyMedicine, 47, 395-400. https://doi.org/10.1016/j.jemermed.2014.06.025
[21]
Lepage, P., Dresse, M.F., Forget, P., Schmitz, V. and Hoyoux, C. (2004) Infections and Antibiotic Prophylaxis in Sickle Cell Disease. Revue Médicale de Liège, 59, 145-148.
[22]
Dayie, N.T.K.D., Tetteh-Ocloo, G., Labi, A., Olayemi, E., Slotved, H., Lartey, M., etal. (2018) Pneumococcal Carriage among Sickle Cell Disease Patients in Accra, Ghana: Risk Factors, Serotypes and Antibiotic Resistance. PLOSONE, 13, e0206728. https://doi.org/10.1371/journal.pone.0206728
[23]
Saidi, H., Smart, L.R., Kamugisha, E., Ambrose, E.E., Soka, D., Peck, R.N., etal. (2016) Complications of Sickle Cell Anaemia in Children in Northwestern Tanzania. Hematology, 21, 248-256. https://doi.org/10.1080/10245332.2015.1101976
[24]
Brown, B.J., Madu, A., Sangeda, R.Z., Nkya, S., Peprah, E., Paintsil, V., etal. (2021) Utilization of Pneumococcal Vaccine and Penicillin Prophylaxis in Sickle Cell Disease in Three African Countries: Assessment among Healthcare Providers in SickleInAfrica. Hemoglobin, 45, 163-170. https://doi.org/10.1080/03630269.2021.1954943
[25]
Kizito, M.E., Mworozi, E., Ndugwa, C. and Serjeant, G.R. (2007) Bacteraemia in Homozygous Sickle Cell Disease in Africa: Is Pneumococcal Prophylaxis Justified? ArchivesofDiseaseinChildhood, 92, 21-23. https://doi.org/10.1136/adc.2005.088807
[26]
Warren, M.D., Arbogast, P.G., Dudley, J.A., Kaltenbach, L., Ray, W.A., Wang, W.C., etal. (2010) Adherence to Prophylactic Antibiotic Guidelines among Medicaid Infants with Sickle Cell Disease. ArchivesofPediatrics&AdolescentMedicine, 164, 298-299. https://doi.org/10.1001/archpediatrics.2009.286
[27]
Odoom, S.F., Newton, S.K., Nakua, E.K., Boahen, K.G., Nguah, S.B., Ansong, D., etal. (2022) Penicillin V Prophylaxis Uptake among Children Living with Sickle Cell Disease in a Specialist Sickle Cell Clinic in Ghana: A Cross‐Sectional Study. HealthScienceReports, 5, e953. https://doi.org/10.1002/hsr2.953
[28]
Enato, I. and Odunvbun, M. (2022) Uptake and Usage of Proguanil as Malaria Chemoprophylaxis and the Socio-Economic Determinants of Proguanil Usage in Children with Sickle Cell Anemia in Benin City. NigerianJournalofClinicalPractice, 25, 903-908. https://doi.org/10.4103/njcp.njcp_1938_21
[29]
Diagne, I., Ndiaye, O., Moreira, C., Signate-Sy, H., Camara, B., Diouf, S., etal. (2000) Les syndromes drépanocytaires majeurs en pédiatrie à Dakar (Sénégal). ArchivesdePédiatrie, 7, 16-24. https://doi.org/10.1016/s0929-693x(00)88912-5
[30]
Jarovsky, D., Bastos, P.R., de Matos, S.F., Almeida, F.J., Sáfadi, M.A.P., Hegg, I.C.O., etal. (2022) Vaccination in Pediatric Patients with Sickle-Cell Disease: Uptake Report and Mini-Review. JournalofTropicalPediatrics, 68, fmac034. https://doi.org/10.1093/tropej/fmac034
